Thoratec paracorporeal biventricular assist device therapy: the Freiburg experience

Brehm, Kerstin; Heilmann, Claudia; Siepe, Matthias; Benk, Christoph; Beyersdorf, Friedhelm; Schlensak, Christian

doi:10.1016/j.ejcts.2011.04.002

Cited by 4 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same limitations apply to existing paracorporeal RVAD and BiVAD systems. [19][20][21] Our institutional configuration of femoral venous cannulation for inflow and PA trunk for outflow enables removal of VPA-ECLS without reoperation, eliminating these risks. A similar procedure was reported by Saeed and colleagues 22 in 21 patients using the Levitronix CentriMag (Thoratec, Pleasanton, Calif) as temporary RV support.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of venopulmonary arterial extracorporeal life support as temporary right ventricular support after left ventricular assist implantation

Shehab

Rao

Macdonald

et al. 2018

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes of venopulmonary arterial extracorporeal life support as temporary right ventricular support after left ventricular assist implantation

Shehab

Rao

Macdonald

et al. 2018

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

show abstract

“…4 A Toronto group examined survival of patients implanted with the ABIOMED BVS 5000 (ABIOMED Inc, CA). In Germany, Brehm and colleagues investigated survival to transplant for 39 acute and chronic heart failure patients on the paracorporeal ventricular assist device (Thoratec Corporation, Pleasanton, CA).…”

Section: Discussionmentioning

confidence: 99%

Clinical Indications for Implantation of the Total Artificial Heart

et al. 2014

View full text Add to dashboard Cite

The total artificial heart (TAH) is effective for bridging patients with biventricular heart failure (BiVHF) to transplantation. It consists of two pneumatic pumps with four mechanical valves that replace nearly the entire myocardium, thus also making it effective therapy for heart failure from alternative (ALT) anatomical and pathophysiological causes that preclude left ventricular assist device (LVAD). This report reviews the clinical indications and outcomes for TAH implantation at our institution from 2006 to 2012. We sought to characterize and compare survival to transplant for patients with BiVHF to those with ALT indications. The overall survival to transplant for all patients was 86% (57/66). There was a trend towards decreased survival to transplantation in the ALT group compared with the BiVHF group (77% vs. 93%, HR 0.42 [95% confidence interval 0.1, 1.7], log-rank test: p = 0.2). This was likely driven by certain high risk subgroups of allograft failure, LVAD failure, and acute postinfarct shock.

show abstract

“…Clinically important BIVADs include the Thoratec (Pierce-Donachy) VA (Pleasanton, CA, USA) and the Berlin Heart Excor. Both are extracorporeal replacement pumps with transcutaneous guided cannulas for blood drainage and supply (17,18).…”

Section: Types Of Devicesmentioning

confidence: 99%

Post-operative infection in mechanical circulatory support patients

Tan

Zeng

2020

Ann Transl Med

View full text Add to dashboard Cite

The management of end stage heart failure has changed dramatically in recent years with the advent of mechanical circulatory support devices as well as rapid improvement and increased availability of these devices. With the improvements in survival and quality of life in these patients, post-operative infections become a significant contribution to morbidity and mortality. Post-operative infections need to be adequately addressed in a timely fashion by early diagnosis and appropriate treatment. Recognizing risk factors for infection and instituting good infection control measures is also key in caring for these patients. Multiple patient and device factors have been shown to be correlated with increased post-operative infections, and cellular immunity is also impaired in patients on ventricular assist devices (VAD). Cultures should be taken prior to starting antimicrobial treatment. Empirical treatment needs to account for common pathogens, local microbial resistance and subsequently be culture guided once results are available.Patients on extracorporeal membrane oxygenation present a unique challenge with drug dosing due to altered pharmacokinetics. VAD related and VAD specific infections require appropriate wound care and possible surgical intervention. This narrative review summarizes the literature available for the management and prevention of post-operative infections in patients with mechanical circulatory devices. Vigilance in identifying risk factors, prompt treatment and active prevention is crucial to the management.

show abstract

Thoratec paracorporeal biventricular assist device therapy: the Freiburg experience

Cited by 4 publications

References 23 publications

Outcomes of venopulmonary arterial extracorporeal life support as temporary right ventricular support after left ventricular assist implantation

Outcomes of venopulmonary arterial extracorporeal life support as temporary right ventricular support after left ventricular assist implantation

Clinical Indications for Implantation of the Total Artificial Heart

Post-operative infection in mechanical circulatory support patients

Contact Info

Product

Resources

About